Phase Ib/II Study of Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Uproleselan Plus Cladribine Plus LDAC in Patients With Treated Secondary AML (TS-AML)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Uproleselan (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 31 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results (n=20) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2023 Results presented in the GlycoMimetics Media Release.